dsip mastery course
Unit 7 of 11
safety profile
what we know, what we don't, and why IV-only creates a ceiling
tolerated in small IV studies -- that's the entire database
DSIP human studies generally report good tolerability at IV doses used in research -- no classic sedation, no respiratory depression, headache among the few noted adverse events in the withdrawal cohort. But "tolerated in small IV studies" is a very different claim from "safe for community subcutaneous use." The long-term safety database simply does not exist. This content is for educational purposes only and is not medical advice.
Not medical advice. This unit describes research data only. DSIP is not FDA-approved. Nothing here constitutes medical advice or a recommendation to use this compound. Consult a licensed physician for any health decisions.
generally tolerated
in published IV studies
no sedation
documented in sleep trials
unknown long-term
safety data absent
safety comparison
Compare DSIP's known safety profile to other sleep pharmacology.
what is known about DSIP
- IV tolerability: generally good in <300 published subjects
- sedation: not documented in clinical trials
- respiratory depression: not reported
what is unknown about DSIP
- long-term effects: no data beyond short study windows
- SC/intranasal safety: not validated in any human study
- drug interactions: systematically unstudied
safety profile comparison